Concert Pharma

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones.

Concert Pharmaceuticals: Negative Spread But Interesting CVR

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.

CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders

Albireo Pharma

Evoqua Water Technologies

Leap Therapeutics

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor  New York, NY 10007 (212) 682-3025  (888) 593-4771 stockinfo@weisslawllp.com Evoqua Water Technologies Corp. (NYSE: AQUA) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem").

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

The company is changing hands in a deal worth at least $576 million.

Why Concert Pharmaceuticals Stock Rocketed Higher This Week

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Concert will receive $8.00 in cash plus one contingent value right (CVR) (entitling its holder to receive up to an additional $3.50 per share of common stock in cash upon achieving certain net sales milestones) for each share of Concert that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE

NEW YORK , Jan. 19, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $8.00 in cash for each share of Concert common stock owned, plus one non-tradeable contingent value right ("CVR") per share.

SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating Concert Pharmaceuticals, Inc. ("Concert") (NASDAQ: CNCE) regarding possible breaches of fiduciary duties and other violations of law related to Concert's agreement to be acquired by Sun Pharmaceutical Industries Limited.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-concert-pharmaceuticals-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Concert Pharmaceuticals, Inc. Buyout

MILWAUKEE , Jan. 19, 2023 /PRNewswire/ -- Ademi LLP is investigating Concert (NASDAQ: CNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma.  Click here to learn how to join the action https://www.ademilaw.com/case/concert-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods.

CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales Milestones MUMBAI, India and LEXINGTON, Mass. , Jan. 19, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) ("Concert") today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Concert (CNCE) Moves 19.3% Higher: Will This Strength Last?

MELBOURNE, Australia--( BUSINESS WIRE )--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert's investigational oral medicine deuruxolitinib (CTP-543) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The World Congress presentation includes new analyses from THRIVE‑AA1 showing the effect of deuruxolitinib on regrowth of scalp hair based on disease severity and duration of current episode of hair loss. The data are being presented by Brett King, M.D., Department of Dermatology, Yale University School of Medicine and clinical investigator of THRIVE-AA1.

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and Investor Relation Roger Tung - President and Chief Executive Officer Marc Becker - Chief Financial Officer James Cassella - Chief Development Officer Nancy Stuart - Chief Operating Officer Conference Call Participants Maury Raycroft - Jefferies Leszek Sulewski - Truist Sean Kim - JonesTrading Jason Butler - JMP Securities Operator Good day and thank you for standing by. And welcome to Concert Pharmaceuticals Third Quarter 2022 Investor Call.

Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates

Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022

MILAN--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Dr. Brett King, Yale University School of Medicine, presents CTP-543 THRIVE-AA1 Phase 3 data during the EADV Late Breaking News Session.

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #ConcertPharmaceuticals--Listen to Concert's on-demand webcast at the H.C. Wainwright Conference beginning at 7:00 am ET on September 12, 2022.

Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 126.6% in Concert (CNCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Concert (CNCE) Could Surge 127%: Read This Before Placing a Bet

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's CTP-543 THRIVE-AA1 Phase 3 results will be presented as a late breaking oral presentation at EADV.

Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--BVF Partners and RA Capital have exercised their remaining tranche 1 warrants resulting in proceeds of $20.9 million to the Company.

News for Concert Pharma Stock (CNCE)